Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA030 in Overweight or Obese Participants
NCT07479862Phase 1Recruiting
- Sponsor
- Suzhou Siran Biotech
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Dose escalation of SA030 with Matching placebo of SA030 (2 arms). Primary endpoints: Number of participants with adverse events (AEs) and serious adverse events (SAEs) at 6 months and Number of participants with clinical significant laboratory abnormalities at 6 months. Started Apr 2026; status: recruiting.
02
Drugs
SA030
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07479862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479862.